Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  palifermin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-23 of 23 for your search:
Start Over
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050100, NCT00352703
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040122, NCT00393822
Phase III Randomized Study of Recombinant Human Keratinocyte Growth Factor in Reducing Therapy-Induced Oral Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0012064, AMGEN-KGF-20000162, FHCRC-1612.00, MSKCC-01065, NCI-G01-1961
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020402, NCT00101582
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040118, NCT00131638
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050219, NCT00434161
Phase III Randomized Study of Standard Induction Chemotherapy With or Without Nelarabine or Rituximab in Patients With Newly Diagnosed, Previously Untreated Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Supportive care, Treatment
Status: Unknown
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma Undergoing High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-97112, AMGEN-KGF-960189, NCI-G97-1368
Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy (Summary Last Modified 03/2000)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Adult
Sponsor: NCI
Protocol IDs: RPCI-DS-97-33, AMGEN-KGF-970149-08, NCI-G98-1397
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20030185, NCT00094861
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040213, NCT00189488
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2004-0511, NCT00267046
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Closed
Age: 12 to 70
Sponsor: Other
Protocol IDs: 2010-0142, NCI-2012-01885, NCT01200329
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2010-0506, NCI-2012-01906, NCT01237951
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 12-388, NCT01746173
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Phase: Phase I
Type: Supportive care
Status: Completed
Age: 18 to 76
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010182, NCT00070616
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Phase: Phase I
Type: Treatment
Status: Completed
Age: 1 to 16
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010133, NCT00460421
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000547155, P30CA022453, WSU-2006-119, NCT00482846
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase: Phase I
Type: Supportive care
Status: Completed
Age: 2 to 18
Sponsor: Other
Protocol IDs: PALSCT, NCT00701688
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 2437.00, NCI-2010-01711, NCT01233921
Start Over